ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, in imatinib-sensitive/resistant BCR-ABL-positive CML cells, MAKV-8 in combination with imatinib displayed substantial anti-tumor properties, while healthy cell types exposed to this co-therapy showed relatively minimal impact.